Related Experiment Video

Updated: Oct 4, 2026

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
08:18

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Published on: January 7, 2019

Developing a clinical strategy for cholesterol management in an era of unanswered questions

B J Ansell1

  • 1Center for Primary-Care Based Cardiovascular Disease Prevention, Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California, Los Angeles School of Medicine, USA. bansell@mednet.ucla.edu

The American Journal of Cardiology
|August 25, 2001
PubMed

Insights

Recent trials show cholesterol therapies reduce cardiovascular events. Further research is needed on optimal lipid-lowering intensity and treatment for diverse populations like women and diabetics.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Lipid Metabolism

Background:

  • Cholesterol-lowering therapies have demonstrated efficacy in reducing cardiovascular events.
  • Unanswered questions persist regarding optimal lipid-lowering therapy intensity and the role of specific lipid fractions.
  • Limited data exist for specific populations such as women, the elderly, and patients with diabetes.

Purpose of the Study:

  • To address remaining questions in lipid-lowering therapy.
  • To determine optimal treatment strategies for underrepresented groups in clinical trials.
  • To guide clinical practice based on current evidence and ongoing research.

Main Methods:

  • Review of recent clinical trial data.
  • Analysis of lipid profiles including high-density lipoprotein cholesterol and triglycerides.
  • Consideration of treatment outcomes in diverse patient demographics.

Main Results:

  • Clinical trials support the use of cholesterol-lowering therapies.
  • Optimal intensity and specific lipid targets require further investigation.
  • Treatment strategies for women, elderly, and diabetic patients need refinement.

Conclusions:

  • Current evidence supports lipid-lowering therapy for cardiovascular risk reduction.
  • Further studies are essential to define optimal treatment intensity and strategies for specific populations.
  • An interim clinical approach integrating recent findings is recommended.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...